CRISPR-Cas9-Mediated Correction of the 1.02 kb Common Deletion in CLN3 in Induced Pluripotent Stem Cells from Patients with Batten Disease

被引:13
作者
Burnight, Erin R. [1 ,2 ]
Bohrer, Laura R. [1 ,2 ]
Giacalone, Joseph C. [1 ,2 ]
Klaahsen, Darcey L. [1 ,2 ]
Daggett, Heather T. [1 ,2 ]
East, Jade S. [1 ,2 ]
Madumba, Robert A. [1 ,2 ]
Worthington, Kristan S. [1 ,3 ]
Mullins, Robert F. [1 ,2 ]
Stone, Edwin M. [1 ,2 ]
Tucker, Budd A. [1 ,2 ]
Wiley, Luke A. [1 ,2 ]
机构
[1] Univ Iowa, Carver Coll Med, Inst Vis Res, 375 Newton Rd, Iowa City, IA 52242 USA
[2] Univ Iowa, Carver Coll Med, Dept Ophthalmol & Visual Sci, 375 Newton Rd, Iowa City, IA 52242 USA
[3] Univ Iowa, Dept Biomed Engn, Iowa City, IA 52242 USA
来源
CRISPR JOURNAL | 2018年 / 1卷 / 01期
基金
美国国家卫生研究院;
关键词
NEURONAL CEROID-LIPOFUSCINOSIS; MOUSE MODEL; IN-VITRO; MUTATIONS; DESIGN; SEQ;
D O I
10.1089/crispr.2017.0015
中图分类号
Q3 [遗传学];
学科分类号
071007 ; 090102 ;
摘要
Juvenile neuronal ceroid lipofuscinosis (Batten disease) is a rare progressive neurodegenerative disorder caused by mutations in CLN3. Patients present with early-onset retinal degeneration, followed by epilepsy, progressive motor deficits, cognitive decline, and premature death. Approximately 85% of individuals with Batten disease harbor at least one allele containing a 1.02 kb genomic deletion spanning exons 7 and 8. This study demonstrates CRISPR-Cas9-based homology-dependent repair of this mutation in induced pluripotent stem cells generated from two independent patients: one homozygous and one compound heterozygous for the 1.02 kb deletion. Our strategy included delivery of a construct that carried >3 kb of DNA: wild-type CLN3 sequence and a LoxP-flanked, puromycin resistance cassette for positive selection. This strategy resulted in correction at the genomic DNA and mRNA levels in the two independent patient lines. These CRISPR-corrected isogenic cell lines will be a valuable tool for disease modeling and autologous retinal cell replacement.
引用
收藏
页码:75 / 87
页数:13
相关论文
共 42 条
[21]   In vivo Editing of the Human Mutant Rhodopsin Gene by Electroporation of Plasmid-based CRISPR/Cas9 in the Mouse Retina [J].
Latella, Maria Carmela ;
Di Salvo, Maria Teresa ;
Cocchiarella, Fabienne ;
Benati, Daniela ;
Grisendi, Giulia ;
Comitato, Antonella ;
Marigo, Valeria ;
Recchia, Alessandra .
MOLECULAR THERAPY-NUCLEIC ACIDS, 2016, 5 :1-12
[22]   Enhanced homology-directed human genome engineering by controlled timing of CRISPR/Cas9 delivery [J].
Lin, Steven ;
Staahl, Brett ;
Alla, Ravi K. ;
Doudna, Jennifer A. .
ELIFE, 2014, 3 :e04766
[23]   Human iPSC models of neuronal ceroid lipofuscinosis capture distinct effects of TPP1 and CLN3 mutations on the endocytic pathway [J].
Lojewski, Xenia ;
Staropoli, John F. ;
Biswas-Legrand, Sunita ;
Simas, Alexandra M. ;
Haliw, Larissa ;
Selig, Martin K. ;
Coppel, Scott H. ;
Goss, Kendrick A. ;
Petcherski, Anton ;
Chandrachud, Uma ;
Sheridan, Steven D. ;
Lucente, Diane ;
Sims, Katherine B. ;
Gusella, James F. ;
Sondhi, Dolan ;
Crystal, Ronald G. ;
Reinhardt, Peter ;
Sterneckert, Jared ;
Schoeler, Hans ;
Haggarty, Stephen J. ;
Storch, Alexander ;
Hermann, Andreas ;
Cotman, Susan L. .
HUMAN MOLECULAR GENETICS, 2014, 23 (08) :2005-2022
[24]   RNA-Guided Human Genome Engineering via Cas9 [J].
Mali, Prashant ;
Yang, Luhan ;
Esvelt, Kevin M. ;
Aach, John ;
Guell, Marc ;
DiCarlo, James E. ;
Norville, Julie E. ;
Church, George M. .
SCIENCE, 2013, 339 (6121) :823-826
[25]   Intracellular trafficking of CLN3, the protein underlying the childhood neurodegenerative disease, Batten disease [J].
Mao, QW ;
Xia, HB ;
Davidson, BL .
FEBS LETTERS, 2003, 555 (02) :351-357
[26]   Membrane topology of CLN3, the protein underlying Batten disease [J].
Mao, QW ;
Foster, BJ ;
Xia, HB ;
Davidson, BL .
FEBS LETTERS, 2003, 541 (1-3) :40-46
[27]   Editing an α-globin enhancer in primary human hematopoietic stem cells as a treatment for β-thalassemia [J].
Mettananda, Sachith ;
Fisher, Chris A. ;
Hay, Deborah ;
Badat, Mohsin ;
Quek, Lynn ;
Clark, Kevin ;
Hublitz, Philip ;
Downes, Damien ;
Kerry, Jon ;
Gosden, Matthew ;
Telenius, Jelena ;
Sloane-Stanley, Jackie A. ;
Faustino, Paula ;
Coelho, Andreia ;
Doondeea, Jessica ;
Usukhbayar, Batchimeg ;
Sopp, Paul ;
Sharpe, Jacqueline A. ;
Hughes, Jim R. ;
Vyas, Paresh ;
Gibbons, Richard J. ;
Higgs, Douglas R. .
NATURE COMMUNICATIONS, 2017, 8
[28]   Targeted disruption of the Cln3 gene provides a mouse model for Batten disease [J].
Mitchison, HM ;
Bernard, DJ ;
Greene, NDE ;
Cooper, JD ;
Junaid, MA ;
Pullarkat, RK ;
de Vos, N ;
Breuning, MH ;
Owens, JW ;
Mobley, WC ;
Gardiner, RM ;
Lake, BD ;
Taschner, PEM ;
Nussbaum, RL .
NEUROBIOLOGY OF DISEASE, 1999, 6 (05) :321-334
[29]   CRISPR/Cas9 Editing of the Mutant Huntingtin Allele In Vitro and In Vivo [J].
Monteys, Alex Mas ;
Ebanks, Shauna A. ;
Keiser, Megan S. ;
Davidson, Beverly L. .
MOLECULAR THERAPY, 2017, 25 (01) :12-23
[30]   CLN3, the protein associated with batten disease: Structure, function and localization [J].
Phillips, SN ;
Benedict, JW ;
Weimer, JM ;
Pearce, DA .
JOURNAL OF NEUROSCIENCE RESEARCH, 2005, 79 (05) :573-583